June 18th 2025
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
Treating Patients with RCC and Brain, Liver, or Bone Metastases
March 19th 2024Panelists discuss systemic therapy approaches for RCC patients presenting with brain, liver, or bone metastases, noting more limited efficacy of IO-IO therapy in brain metastases and tendencies to use IO-TKI therapy for aggressive or rapidly progressing disease.
Managing Immune-Related Toxicities with Frontline RCC Therapies
March 12th 2024Expert panelists discuss the importance of rapid improvement within 24-72 hours with steroids for managing unpredictable immune-related toxicities that can occur with frontline IO-IO or IO-TKI regimens for patients with RCC.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
Apalutamide/AAP Improves Outcomes Without Negative HRQOL Impact in Prostate Cancer
January 26th 2024Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.
Reflections on Novel Targets and Emerging Regimens for RCC
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.